Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Tovorafenib by Day One Biopharmaceuticals for Craniopharyngioma: Likelihood of Approval
Tovorafenib is under clinical development by Day One Biopharmaceuticals and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase...